The data shown below were collected from the profiles of 3 X users who shared this research output. Click here to find out more about how the information was compiled.
As of 1 July 2024, you may notice a temporary increase in the numbers of X profiles with Unknown location. Click here to learn more.
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
| Title |
Safety and Efficacy of Sintilimab and Anlotinib as First Line Treatment for Advanced Hepatocellular Carcinoma (KEEP-G04): A Single-Arm Phase 2 Study
|
|---|---|
| Published in |
Frontiers in oncology, May 2022
|
| DOI | 10.3389/fonc.2022.909035 |
| Pubmed ID | |
| Authors |
Xiaofeng Chen, Wei Li, Xiaofeng Wu, Fengjiao Zhao, Deqiang Wang, Hao Wu, Yanhong Gu, Xiao Li, Xiaofeng Qian, Jun Hu, Changxian Li, Yongxiang Xia, Jianhua Rao, Xinzheng Dai, Qianwen Shao, Jie Tang, Xiangcheng Li, Yongqian Shu |
X Demographics
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 3 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 3 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 10 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 10 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Bachelor | 2 | 20% |
| Student > Ph. D. Student | 1 | 10% |
| Researcher | 1 | 10% |
| Unknown | 6 | 60% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 2 | 20% |
| Unknown | 8 | 80% |
Attention Score in Context
This research output has an Altmetric Attention Score of 2. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 18 June 2022.
All research outputs
#16,591,579
of 26,169,168 outputs
Outputs from Frontiers in oncology
#5,841
of 22,913 outputs
Outputs of similar age
#231,921
of 449,945 outputs
Outputs of similar age from Frontiers in oncology
#380
of 1,662 outputs
Altmetric has tracked 26,169,168 research outputs across all sources so far. This one is in the 34th percentile – i.e., 34% of other outputs scored the same or lower than it.
So far Altmetric has tracked 22,913 research outputs from this source. They receive a mean Attention Score of 3.1. This one has gotten more attention than average, scoring higher than 70% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 449,945 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 44th percentile – i.e., 44% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 1,662 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 74% of its contemporaries.